HIV‑1 Genotype and Coreceptor Tropism, Ultradeep Sequencing
Use
Genotypic testing of HIV‑1 coreceptor tropism helps determine whether the patient’s virus uses CCR5 (R5), CXCR4 (X4), or both (dual/mixed) coreceptors, which informs eligibility for CCR5‑antagonist therapy such as maraviroc. Ultradeep sequencing increases sensitivity to detect minority X4‑using variants (≥2%), which are clinically significant in predicting lack of response to CCR5 antagonists. Suitable for treatment‑naïve and treatment‑experienced patients.
Special Instructions
Not provided.
Limitations
Genotypic tropism testing may be limited by low viral load (<1,000 copies/mL), which may prevent RNA amplification—alternative proviral DNA tropism testing is available in such cases. Although ultradeep sequencing increases sensitivity, detection limits may vary based on viral load. Genotypic test performance may vary by HIV‑1 subtype, with reduced certainty for subtypes AE, F, and G. The assay is lab‑developed and not FDA‑cleared.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-14 days
Related Documents
For more information, please review the documents below
Not provided.
Other tests from different labs that may be relevant